Carregando...
TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy
BACKGROUND: Immunotherapies have revolutionized cancer treatment. Unlike chemotherapies, immune agents often take longer to show benefit, and the complex and unique mechanism of action of these agents renders the use of multiple endpoints more appropriate in some trials. These new features of immuno...
Na minha lista:
| Publicado no: | J Natl Cancer Inst |
|---|---|
| Principais autores: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8204709/ https://ncbi.nlm.nih.gov/pubmed/30924863 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djz049 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|